Advancing Selectivity in Cancer Treatment
LabGenius to Reveal AI-Designed Cancer Drug Data
Preclinical results for LGTX-101 show high selectivity and tumor regression ahead of AACR 2026.
A high-tech digital display showing a 3D molecular model of an antibody structure in a bright laboratory setting.
Photo: Avantgarde News
LabGenius announced it will present preclinical data for its AI-designed antibody, LGTX-101, at the American Association for Cancer Research (AACR) 2026 annual meeting in San Diego [1]. The machine-learning derived T-cell engager demonstrated high tumor selectivity and successful regression in vivo [1][2]. Research indicates that LGTX-101 achieved a 400-fold increase in tumor-killing selectivity compared to existing clinical benchmarks [2]. The company utilized its proprietary machine-learning platform to optimize the molecule's performance [2]. These findings suggest a significant advancement in the precision of cancer immunotherapies [1][2].
Editorial notes
Transparency note
Drafted with LLM; human-edited
- AI assisted
- Yes
- Human review
- Yes
- Last updated
Risk assessment
The source list contains only two independent domains, failing the requirement for at least three independent sources.
Sources
- 1.↗
drugtargetreview.com
https://www.drugtargetreview.com/news/194251/new-ai-designed-t-cell-engager-lgtx-101-to-be-presented-at-aacr-in-san-diego/
- 2.↗
labgeniustx.com
https://labgeniustx.com/press-release-labgenius-debuts-t-cell-engager-optimisation-capability-that-yields-molecules-with-400-fold-tumour-killing-selectivity-versus-clinical-benchmark/
Related stories
View all
Topics
About the author
Avantgarde News Desk covers advancing selectivity in cancer treatment and editorial analysis for Avantgarde News.